Zobrazit v EDS

The associations of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as add‐on to metformin with fracture risk in patients with type 2 diabetes mellitus

Uloženo v:
Podrobná bibliografie
Název: The associations of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as add‐on to metformin with fracture risk in patients with type 2 diabetes mellitus
Autoři: Veerle van Hulten, Johanna H. M. Driessen, Jakob K. Starup‐Linde, Zheer K. Al‐Mashhadi, Rikke Viggers, Olaf H. Klungel, Patrick C. Souverein, Peter Vestergaard, Coen D. A. Stehouwer, Joop P. van den Bergh
Přispěvatelé: Sub Gen. Pharmacoepi and Clinical Pharm, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology
Zdroj: van Hulten, V, Driessen, J H M, Starup-Linde, J K, Al-Mashhadi, Z K, Viggers, R, Klungel, O H, Souverein, P C, Vestergaard, P, Stehouwer, C D A & van den Bergh, J P 2023, 'The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus', Diabetes, Obesity and Metabolism, vol. 25, no. 11, pp. 3235-3247. https://doi.org/10.1111/dom.15220
Informace o vydavateli: Wiley, 2023.
Rok vydání: 2023
Témata: Male, pharmacoepidemiology, Endocrinology, Diabetes and Metabolism, Glucose/therapeutic use, Hypoglycemic Agents/adverse effects, Cohort Studies, Fractures, Bone, Endocrinology, SDG 3 - Good Health and Well-being, Internal Medicine, cohort study, DPP-4 inhibitor, Humans, Hypoglycemic Agents, Dipeptidyl-Peptidase IV Inhibitors/adverse effects, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Sodium-Glucose Transporter 2 Inhibitors, Metformin/adverse effects, Retrospective Studies, Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2/complications, Sodium, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, diabetes complications, SGLT2 inhibitor, Metformin, 3. Good health, Glucose, Diabetes Mellitus, Type 2, Fractures, Bone/epidemiology, Female, type 2 diabetes, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/metabolism
Popis: AimTo investigate whether sodium‐glucose cotransporter‐2 (SGLT2) inhibitor use as compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitor use as add‐on to metformin is associated with the risk of any fracture or major osteoporotic fractures (MOFs).MethodsA cohort study using the Clinical Practice Research Datalink (CPRD) Aurum database was conducted. All patients aged 18 years and older with a first‐ever prescription for a DPP‐4 inhibitor or an SGLT2 inhibitor as add‐on to metformin between January 1, 2013 and June 30, 2020 were selected. Patients starting with SGLT2 inhibitors were matched (up to 1:3) on propensity scores to patients starting with DPP‐4 inhibitors. Propensity scores were calculated based on sex, age, body mass index, comorbidities, comedication and lifestyle factors. Cox proportional hazard models were used to estimate the risk of fracture with SGLT2 inhibitor use as compared to DPP‐4 inhibitor use.ResultsA total of 13 807 SGLT2 inhibitor users (age 55.4 ± 10.6 years, 36.7% female) were included in this study, matched with 28 524 DPP‐4 inhibitor users (age 55.4 ± 8.0 years, 36.4% female). The risk of any fracture with current SGLT2 inhibitor use was similar compared with current DPP‐4 inhibitor use (adjusted hazard ratio [aHR] 1.09, 95% confidence interval [CI] 0.91‐1.31), as was the risk of MOFs (aHR 0.89, 95% CI 0.64‐1.22) and the risk of fractures at any of the individual MOF sites. Additionally, no association was found with duration of SGLT2 inhibitor use (longest duration >811 days) for any of the individual SGLT2 inhibitor agents, or after stratification by sex and age.ConclusionUse of SGLT2 inhibitors was not associated with the risk of any fracture, MOFs or fracture at the individual MOF sites when compared to DPP‐4 inhibitor use.
Druh dokumentu: Article
Popis souboru: application/pdf
Jazyk: English
ISSN: 1463-1326
1462-8902
DOI: 10.1111/dom.15220
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/37503747
https://pure.au.dk/ws/files/411390158/Diabetes_Obesity_Metabolism_-_2023_-_Hulten_-_The_associations_of_sodium_glucose_cotransporter_2_inhibitors_versus.pdf
https://dspace.library.uu.nl/handle/1874/432841
Rights: CC BY NC ND
Přístupové číslo: edsair.doi.dedup.....800070e299716db0cec5c672f0c86298
Databáze: OpenAIRE
Popis
Abstrakt:AimTo investigate whether sodium‐glucose cotransporter‐2 (SGLT2) inhibitor use as compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitor use as add‐on to metformin is associated with the risk of any fracture or major osteoporotic fractures (MOFs).MethodsA cohort study using the Clinical Practice Research Datalink (CPRD) Aurum database was conducted. All patients aged 18 years and older with a first‐ever prescription for a DPP‐4 inhibitor or an SGLT2 inhibitor as add‐on to metformin between January 1, 2013 and June 30, 2020 were selected. Patients starting with SGLT2 inhibitors were matched (up to 1:3) on propensity scores to patients starting with DPP‐4 inhibitors. Propensity scores were calculated based on sex, age, body mass index, comorbidities, comedication and lifestyle factors. Cox proportional hazard models were used to estimate the risk of fracture with SGLT2 inhibitor use as compared to DPP‐4 inhibitor use.ResultsA total of 13 807 SGLT2 inhibitor users (age 55.4 ± 10.6 years, 36.7% female) were included in this study, matched with 28 524 DPP‐4 inhibitor users (age 55.4 ± 8.0 years, 36.4% female). The risk of any fracture with current SGLT2 inhibitor use was similar compared with current DPP‐4 inhibitor use (adjusted hazard ratio [aHR] 1.09, 95% confidence interval [CI] 0.91‐1.31), as was the risk of MOFs (aHR 0.89, 95% CI 0.64‐1.22) and the risk of fractures at any of the individual MOF sites. Additionally, no association was found with duration of SGLT2 inhibitor use (longest duration >811 days) for any of the individual SGLT2 inhibitor agents, or after stratification by sex and age.ConclusionUse of SGLT2 inhibitors was not associated with the risk of any fracture, MOFs or fracture at the individual MOF sites when compared to DPP‐4 inhibitor use.
ISSN:14631326
14628902
DOI:10.1111/dom.15220